Increased angiogenic factors associated with peripheral avascular retina and intravitreous neovascularization: a model of retinopathy of prematurity.
OBJECTIVE
To determine expression of vascular endothelial growth factor (VEGF), pigment epithelium-derived factor, and their respective receptors in retinas using a model of retinopathy of prematurity.


METHODS
Retinas isolated from a 50/10 oxygen (inspired oxygen cycled between 50% oxygen and 10% oxygen every 24 hours)-induced rat model of retinopathy of prematurity (50/10 OIR model), and from room air-raised rat pups (RA) at birth, age 14 days (persistent peripheral avascular retina in the 50/10 OIR model and complete retinal vascularization in RA) and age 18 days (intravitreous neovascularization in the 50/10 OIR model) were analyzed for messenger RNA of VEGF(164), neuropilin 1, neuropilin 2, VEGF receptor 1, VEGF receptor 2, pigment epithelium-derived factor, and pigment epithelium-derived factor receptor by real-time polymerase chain reaction.


RESULTS
In the 50/10 OIR model compared with RA, fold changes in expression of VEGF(164), neuropilin 1, and neuropilin 2 were significantly increased at ages 14 and 18 days. A trend for increased fold change was noted in expression of VEGF receptor 2 at age 14 days and a significant increase at age 18 days in the 50/10 OIR model compared with RA. Pigment epithelium-derived factor receptor was significantly increased at age 14 days in the 50/10 OIR model compared with RA.


CONCLUSIONS
Increased expression of VEGF(164) and angiogenic receptors were found in association with both avascular retina at day 14 and intravitreous neovascularization at day 18 in a relevant model of retinopathy of prematurity.


CONCLUSIONS
Increased VEGF and angiogenic receptors may have a role in the development of peripheral avascular retina and stage 3 retinopathy of prematurity.
Budd
Steven J
SJ
Department of Ophthalmology, School of Medicine, University of North Carolina, 130 Mason Farm Rd, Campus Box 7040, Chapel Hill, NC 27599-7040, USA. hartnet@med.unc.edu
Hartnett
M Elizabeth
ME
D000818:Animals; D000831:Animals, Newborn; D004195:Disease Models, Animal; D005136:Eye Proteins / Q000235:genetics*; D005786:Gene Expression Regulation / Q000502:physiology*; D006801:Humans; D007231:Infant, Newborn; D009414:Nerve Growth Factors / Q000235:genetics*; D039942:Neuropilin-1 / Q000235:genetics; D039943:Neuropilin-2 / Q000235:genetics; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D018013:Receptors, Neuropeptide / Q000235:genetics*; D015861:Retinal Neovascularization / Q000235:genetics*; D012178:Retinopathy of Prematurity / Q000145:classification / Q000235:genetics*; D015843:Serpins / Q000235:genetics*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000235:genetics; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics*; D014822:Vitreous Body / Q000098:blood supply; D000099174:Pigment Epithelium-Derived Factor
D005136:Eye Proteins; D009414:Nerve Growth Factors; D039942:Neuropilin-1; D039943:Neuropilin-2; D012333:RNA, Messenger; D018013:Receptors, Neuropeptide; D015843:Serpins; D042461:Vascular Endothelial Growth Factor A; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2; D000099174:Pigment Epithelium-Derived Factor; C400531:pigment epithelium-derived factor receptor; C467498:vascular endothelial growth factor A, rat
Nat Rev Neurosci. 2003 Aug;4(8):628-36
12894238
Invest Ophthalmol Vis Sci. 2006 Nov;47(11):5047-56
17065526
Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10589-94
17567756
Exp Eye Res. 2009 Nov;89(5):718-27
19576214
Invest Ophthalmol Vis Sci. 1996 Jun;37(7):1322-33
8641835
Invest Ophthalmol Vis Sci. 1984 Oct;25(10):1129-34
6207136
Mol Vis. 2008;14:2499-508
19112532
Exp Eye Res. 2008 Sep;87(3):226-41
18602915
Blood. 2007 Feb 15;109(4):1345-52
17068148
J Clin Invest. 2003 Jul;112(1):50-7
12840058
Arch Dis Child Fetal Neonatal Ed. 2001 Mar;84(2):F106-10
11207226
Invest Ophthalmol Vis Sci. 1995 Jun;36(7):1201-14
7775098
Mol Vis. 2004 Jul 21;10:512-20
15303088
Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10595-600
17567755
Invest Ophthalmol Vis Sci. 2006 Jul;47(7):3151-5
16799062
J Biol Chem. 2006 Dec 8;281(49):38022-37
17032652
FEBS Lett. 2001 Feb 2;489(2-3):270-6
11165263
Nat Rev Cancer. 2008 Aug;8(8):632-45
18580951
J Neurosci. 1995 Jul;15(7 Pt 1):4738-47
7623107
Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3107-14
18378573
J Mol Endocrinol. 2006 Aug;37(1):1-12
16901919
Invest Ophthalmol Vis Sci. 1994 Aug;35(9):3429-35
8056518
Pediatr Res. 1994 Dec;36(6):724-31
7898981
Invest Ophthalmol Vis Sci. 1994 Jan;35(1):101-11
7507904
Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2639-47
16723481
Cancer Res. 2003 Sep 1;63(17):5230-3
14500350
Am J Pathol. 2007 Jul;171(1):53-67
17591953
Arch Ophthalmol. 1996 Oct;114(10):1219-28
8859081
Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):905-9
7846076
Microsc Res Tech. 1997 Jan 1;36(1):1-16
9031257
Nat Med. 2003 Jun;9(6):669-76
12778165
Proc Natl Acad Sci U S A. 1996 May 14;93(10):4851-6
8643492
Nat Genet. 2001 Jun;28(2):131-8
11381259
J Biochem Mol Biol. 2006 Sep 30;39(5):469-78
17002866
Nat Med. 2007 Jul;13(7):868-873
17589522
Lancet. 1995 Dec 2;346(8988):1464-5
7490994
Science. 1999 Jul 9;285(5425):245-8
10398599
Mol Vis. 2008 Feb 11;14:345-57
18334951
Mol Vis. 2007 Jun 12;13:840-53
17615545